Phase II study of single-agent crenolanib in recurrent/refractory glioblastoma with PDGFRA gene amplification
The goal of the pre-screening part of this clinical research study is to learn if you are eligible to be screened to take part in the main research study. The goal of the main part of this clinical research study is to learn if crenolanib can help to control glioblastoma. The safety of the study drug will also be studied.
Disease Group: Brain,CNS
Treatment Agent: Crenolanib
Treatment Location: Only at MDACC
Sponsor: AROG Pharmaceuticals, Inc.
IRB Review and Approval Date: 04/29/2016
Recruitment Status: Open
Projected Accrual: 43
Information and next steps
For general questions about clinical trials: